Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01378676 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT01378676 is a Phase 2 study that has completed, run by Cytokinetics. The registered enrollment target is 49 participants.
The verdict
NCT01378676, a Phase 2 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for 14 days.
Interventions
- DRUG Placebo (Part A)
- DRUG CK-2017357 (Part A)
- DRUG Riluzole 50 MG (Part B)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01378676
The ClinicalTrials.gov registry entry for NCT01378676 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo (Part A) is the first listed.
NCT01378676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01378676 about?
NCT01378676 is a clinical study titled "A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)". The study will generate data on safety, tolerability and pharmacokinetics after multiple daily doses of CK-2017357 in patients with ALS. Patients will be randomized into one of four different treatment groups, receiving daily oral doses of either placebo, 125 mg, 250 mg, or 375 mg of CK-2017357 for ...
What is the current status of trial NCT01378676?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2011-06. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01378676?
The interventions under investigation include: Placebo (Part A) (DRUG), CK-2017357 (Part A) (DRUG), Riluzole 50 MG (Part B) (DRUG).
Who is sponsoring clinical trial NCT01378676?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.